secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001628280-24-035848
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 reports Q2 net income $90.8M on PRV sale; first XOLREMDI sales $0.6M
-----------------------------------------------------------------------

- Q2 net income $90.8M vs net loss $55.7M YoY; includes $105M gain on sale of priority review voucher.
- First product revenue $0.6M from XOLREMDI launch following FDA approval in April 2024 for WHIM syndrome.
- Cash, equivalents, marketable securities $169.5M; operating runway into late 2025 (excl. future revenue).
- Positive interim Phase 2 data for mavorixafor in chronic neutropenia; full results expected Nov 2024; Phase 3 4WARD trial started.
- Plans to submit EMA approval for mavorixafor in WHIM syndrome by early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024035848/0001628280-24-035848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024035848/xfor-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-035848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer